The Warm Revolution: A Meta-Analysis of DCD Versus DBD Liver Transplant Outcomes in the Normothermic Machine Perfusion Era.

Artif OrgansJun 25, 2026 (epub)
Clinical ResearchGeneral SurgeryGastroenterology

Patricia Viana, Luiz Gustavo Albuquerque Mello de Oliveira, Maria Meritxell Roca Mora et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis evaluated outcomes of liver transplants from donation after circulatory death (DCD) versus donation after brain death (DBD) using normothermic machine perfusion (NMP). Involving 18 studies and 1578 livers, it found that DCD grafts had lower organ utilization (RR 0.84) but comparable outcomes in biliary complications and graft survival at one year.

Key findings

  • DCD grafts had significantly lower organ utilization compared to DBD grafts (RR 0.84, p < 0.001).
  • DCD grafts required higher rates of biliary interventions (RR 2.48, p = 0.008).
  • No significant differences were found in early allograft dysfunction or graft survival at one year.

Why it matters

Understanding the comparative outcomes of DCD and DBD liver grafts preserved with NMP is crucial for optimizing donor organ utilization and improving transplant success rates, particularly in settings with limited donor availability.

Source

PubMed · PMID 42350934

Published in Artif Organs. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in General Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.